A*Star

The partners are aiming to generate proteomic and phosphoproteomic data that they can include in Indivumed's global cancer database.

Researchers from A*Star and elsewhere have implicated a recessive mutation in CAMK2A in a neurodevelopmental disorder affecting a pair of siblings.

The technology relates to the isolation and genetic analysis of circulating fetal cells from maternal blood.

The first assay to be developed under the new five-year strategic partnership is a solid biopsy breast cancer assay designed to guide drug selection.

Each panel that the collaborators develop is expected to be highly multiplexed and syndromic, addressing clinically important infectious diseases in Asia.

GUSTO study researchers said maternal lifestyle, fetal genetic, and fetal epigenetic factors affect birth weight and early childhood adiposity.

While gain-of-function mutations lead to congenital arhinia, inactivating mutations lead to an adult-onset muscular dystrophy, the researchers reported.

The partners will collaborate in developing Atreca's single-cell sequencing technology to advance new cancer immunotherapies.